Abstract
In 2008, the United States Preventive Services Task Force (USPSTF) recommended against prostate-specific antigen (PSA) screening for men aged >75 years and extended this to men of all ages in a 2011 draft recommendation that was finalized in 2012. 1 Moyer V.A. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012; 157: 120 Crossref PubMed Scopus (1608) Google Scholar Similar recommendations against PSA were issued by the Canadian Preventive Health Task Force in 2014. 2 Canadian Task Force on Preventive Health Care. Available at: http://canadiantaskforce.ca/ctfphc-guidelines/2014-prostate-cancer/. Accessed May 1, 2015. Google Scholar These guidelines have generated significant controversy and contrast with the recommendations of numerous professional societies for shared decision making about PSA. 3 AUAEarly detection of prostate cancer: American Urological Association Guideline. 2013http://www.auanet.org/education/guidelines/prostate-cancer-detection.cfm Google Scholar Trends in Prostate-specific Antigen Screening, Prostate Biopsies, Urology Visits, and Prostate Cancer Treatments From 2000 to 2012UrologyVol. 86Issue 3PreviewTo determine whether the rates of prostate-specific antigen (PSA) screening, related biopsies and subsequent prostate cancer utilization decreased between 2000 and 2012 in a large, managed care organization. Full-Text PDF ReplyUrologyVol. 86Issue 3PreviewWe thank Drs. Brawley1 and Loeb2 for their thoughtful comments about screening for prostate cancer and the results reported here at Kaiser Permanente Southern California. The evidence about prostate-specific antigen screening for prostate cancer is controversial, particularly in an age where risk stratification is inexact. However, there is little controversy regarding when prostate cancer screening is no longer beneficial, and as such, we have chosen to focus our efforts in reducing unnecessary overscreening, overdiagnosis, and overtreatment in older men. Full-Text PDF
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
